These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 9146820)

  • 21. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance.
    Calsyn DA; Malcy JA; Saxon AJ
    J Subst Abuse Treat; 2006 Mar; 30(2):159-63. PubMed ID: 16490679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
    Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
    J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio.
    Bell J; Shearer J; Ryan A; Graham R; Korompay K; Rizzo S; Sindhusake D; Somogyi AA
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):146-53. PubMed ID: 19586229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The history of the development of buprenorphine as an addiction therapeutic.
    Campbell ND; Lovell AM
    Ann N Y Acad Sci; 2012 Feb; 1248():124-39. PubMed ID: 22256949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
    Renzelli CM; Capretto NA
    J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life among heroin users on buprenorphine versus methadone maintenance.
    Ponizovsky AM; Grinshpoon A
    Am J Drug Alcohol Abuse; 2007; 33(5):631-42. PubMed ID: 17891656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
    Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
    Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
    Mintzer MZ; Correia CJ; Strain EC
    Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Is buprenorphine a potential alternative to methadone for treating pregnant drug users? Inventory of clinical data in the literature].
    Loustauneau A; Auriacombe M; Daulouede JP; Tignol J
    Ann Med Interne (Paris); 2002 Nov; 153(7 Suppl):2S31-6. PubMed ID: 12518080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subjective effects of additional doses of buprenorphine in patients on buprenorphine maintenance.
    Singhal A; Tripathi BM; Pal HR; Jena R; Jain R
    Addict Behav; 2007 Feb; 32(2):320-31. PubMed ID: 16814937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Buprenorphine replacement therapy: a confirmed benefit.
    Prescrire Int; 2006 Apr; 15(82):64-70. PubMed ID: 16604748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users.
    Lubman D; Koutsogiannis Z; Kronborg I
    Drug Alcohol Rev; 2003 Dec; 22(4):433-6. PubMed ID: 14660133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
    Mendelson J; Jones RT
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S29-37. PubMed ID: 12738348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.